Slate Path Capital LP Invests $8.20 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Slate Path Capital LP bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 319,000 shares of the company's stock, valued at approximately $8,198,000. Slate Path Capital LP owned approximately 0.35% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Rock Springs Capital Management LP boosted its stake in NewAmsterdam Pharma by 117.2% in the 4th quarter. Rock Springs Capital Management LP now owns 767,522 shares of the company's stock worth $19,725,000 after purchasing an additional 414,203 shares during the period. Bain Capital Life Sciences Investors LLC boosted its position in shares of NewAmsterdam Pharma by 2.3% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock worth $275,481,000 after acquiring an additional 245,197 shares during the last quarter. Capital World Investors bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth $26,113,000. Capital International Investors purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at $53,007,000. Finally, Marshall Wace LLP increased its holdings in NewAmsterdam Pharma by 161.9% in the 4th quarter. Marshall Wace LLP now owns 288,446 shares of the company's stock valued at $7,413,000 after acquiring an additional 178,322 shares during the last quarter. Institutional investors own 89.89% of the company's stock.

Insider Activity

In other news, Director James N. Topper acquired 1,135 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares of the company's stock, valued at $305,550. This trade represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Stock Performance

NAMS stock traded up $0.05 during midday trading on Friday, reaching $17.52. 345,323 shares of the company traded hands, compared to its average volume of 592,501. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -6.74 and a beta of -0.01. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The business has a 50 day moving average of $19.61 and a 200-day moving average of $21.19.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. Research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NAMS shares. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $42.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Buy" and an average price target of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.